0
0
Home » Pharmaceuticals

Overactive Bladder – Epidemiology Forecast to 2030

Overactive bladder (OAB) syndrome is a group of urinary symptoms, defined as urinary urgency, usually with urinary frequency and nocturia, with or without urgency urinary incontinence (Abrams et al., 2003; Haylen et al., 2010). It is characterized by a frequent and sudden compelling urge to urinate that may be difficult to control. The clinical diagnosis is characterized by urinary urgency, with or without urge incontinence, usually with daytime and nighttime frequency, in the absence of a urinary tract infection or other obvious pathology (Lightner et al., 2019). Based on the presentation, OAB can be of two types: OAB-dry and OAB-wet. OAB that causes a person to urinate frequently and urgently without incontinence is known as OAB-dry. If a person does have urinary frequency and urgency accompanied by urge incontinence, the condition is known as OAB-wet (Anger et al., 2012).

This report provides an overview of the risk factors, comorbidities, and the global and historical epidemiological trends for OAB in the eight major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan, and China). The report includes a 10-year epidemiology forecast for the total prevalent cases and diagnosed prevalent cases of OAB. The total prevalent cases and diagnosed prevalent cases of OAB are segmented by age (5–11 years, 12–17 years, 18–29 years, and by ten-year age group for ages 30 to 80 years and older), sex, and subtype (OAB-dry and OAB-wet). The report also includes the total prevalent cases and diagnosed prevalent cases of OAB further segmented by comorbidities such as benign prostatic hyperplasia, stress incontinence, fecal incontinence, and metabolic syndrome. The following data describes epidemiology of OAB. In the 8MM, GlobalData epidemiologists forecast an increase in the total prevalent cases of OAB from 363,318,429 cases in 2020 to 401,653,622 cases in 2030, at an AGR of 1.06% over the forecast period. Women accounted for more total prevalent cases of OAB than men in the 8MM and it predominantly affects older adults. These findings are in line with the GlobalData estimates and these trends are reflected in GlobalData’s forecast for the total prevalent cases for the 8MM.

Scope

The Overactive Bladder (OAB) Epidemiology Report and Model provide an overview of the risk factors and global trends of OAB in the eight major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan, and China).

The report includes a 10-year epidemiology forecast for the total prevalent cases and diagnosed prevalent cases of OAB. The total prevalent cases and diagnosed prevalent cases of OAB are segmented by age (5–11 years, 12–17 years, 18–29 years, and by ten-year age group for age 30 years up to 80 years and older), sex, and subtype (OAB-dry and OAB-wet). The report also includes the total prevalent cases and diagnosed prevalent cases of OAB further segmented by comorbidities such as benign prostatic hyperplasia, stress incontinence, fecal incontinence, and metabolic syndrome.

The OAB epidemiology report and model were written and developed by Masters- and PhD-level epidemiologists.

• The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 8MM.

• The Epidemiology Model is easy to navigate, interactive with dashboards, and epidemiology-based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources.

Reasons to Buy

The Overactive Bladder Epidemiology series will allow you to:

Develop business strategies by understanding the trends shaping and driving the global OAB market.

Quantify patient populations in the global OAB market to improve product design, pricing, and launch plans.

Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for OAB therapeutics in each of the markets covered.

Understand magnitude of OAB population by subtype, and comorbidities.

Table of Contents

| Contents

| List of Tables

| List of Figures

| About GlobalData

1 Overactive Bladder (OAB): Executive Summary

1.1 Related Reports

1.2 Upcoming Reports

2 Epidemiology

2.1 Disease Background

2.2 Risk Factors and Comorbidities

2.3 Global and Historical Trends

2.4 8MM Forecast Methodology

2.4.1 Sources

2.4.2 Forecast Assumptions and Methods

2.4.3 Forecast Assumptions and Methods: Total Prevalent Cases of OAB

2.4.4 Forecast Assumptions and Methods: Total Prevalent Cases of OAB by Presentation

2.4.5 Forecast Assumptions and Methods: Total Prevalent Cases of OAB by Comorbidity

2.4.6 Diagnosed Prevalent Cases of OAB

2.5 Epidemiological Forecast for OAB (2020–2030)

2.5.1 Total Prevalent Cases of OAB

2.5.2 Age-Specific Total Prevalent Cases of OAB

2.5.3 Sex-Specific Total Prevalent Cases of OAB

2.5.4 Total Prevalent Cases of OAB by Presentation

2.5.5 Total Prevalent Cases of OAB by Comorbidity

2.5.6 Diagnosed Prevalent Cases of OAB

2.5.7 Age-Specific Diagnosed Prevalent Cases of OAB

2.5.8 Sex-Specific Diagnosed Prevalent Cases of OAB

2.5.9 Diagnosed Prevalent Cases of OAB by Presentation

2.5.10 Diagnosed Prevalent Cases of OAB by Comorbidity

2.6 Discussion

2.6.1 Epidemiological Forecast Insight

2.6.2 COVID-19 Impact

2.6.3 Limitations of the Analysis

2.6.4 Strengths of the Analysis

3 Appendix

3.1 Bibliography

3.2 Primary Research – KOLs Interviewed for this Report

3.3 About the Authors

3.3.1 Epidemiologist

3.3.2 Reviewers

3.3.3 Global Director of Therapy Analysis and Epidemiology

3.3.4 Global Head and EVP of Healthcare Operations and Strategy

3.4 Contact Us

List of Tables

Table 1: Risk Factors and Comorbidities for Overactive Bladder

Table 2: Total Prevalent Cases of OAB by Comorbidity

Table 3: Diagnosed Prevalent Cases of OAB by Comorbidity

List of Figures

Figure 1: 8MM, Total Prevalent Cases of Overactive Bladder, Both Sexes, N, Ages ≥5 Years, 2020 and 2030

Figure 2: 8MM, Diagnosed Prevalent Cases of Overactive Bladder, Both Sexes, N, Ages ≥5 Years, 2020 and 2030

Figure 3: 8MM, Total Prevalence of OAB, Men and Women, %, Ages ≥5 Years, 2020

Figure 4: 8MM, Diagnosed Prevalence of Overactive Bladder, Men and Women, %, Ages ≥5 Years, 2020

Figure 5: 8MM, Sources Used and Not Used to Forecast the Total Prevalent Cases of OAB

Figure 6: 8MM, Sources Used to Forecast the Total Prevalent Cases of OAB by Presentation

Figure 7: 8MM, Sources Used to Forecast the Total Prevalent Cases of OAB by Comorbidity

Figure 8: 8MM, Total Prevalent Cases of Overactive Bladder, N, Both Sexes, Ages ≥5 Years, 2020

Figure 9: 8MM, Total Prevalent Cases of OAB by Age, N, Both Sexes, 2020

Figure 10: 8MM, Total Prevalent Cases of OAB by Sex, N, Ages ≥5 Years, 2020

Figure 11: 8MM, Total Prevalent Cases of OAB by Presentation, N, Both Sexes, Ages ≥5 Years, 2020

Figure 12: 8MM, Diagnosed Prevalent Cases of OAB, N, Both Sexes, Ages ≥5 Years, 2020

Figure 13: 8MM, Diagnosed Prevalent Cases of OAB by Age, N, Both Sexes, 2020

Figure 14: 8MM, Diagnosed Prevalent Cases of OAB by Sex, N, Ages ≥5 Years, 2020

Figure 15: 8MM, Diagnosed Prevalent Cases of OAB by Presentation, N, Both Sexes, Ages ≥5 Years, 2020

    Pricing

Discounts available for multiple purchases.

reportstore@globaldata.com
+44 20 7947 2960

Join our mailing list

Saved reports